{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:31:31Z","timestamp":1768883491073,"version":"3.49.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ygyno.2017.06.002","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T14:32:30Z","timestamp":1496845950000},"page":"217-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-4858","authenticated-orcid":false,"given":"Leslie M.","family":"Randall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-2453","authenticated-orcid":false,"given":"Adam","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine T.","family":"Witkop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bethan Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen Blair","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Robson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.06.002_bb0005","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2012.12.015","article-title":"Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing","volume":"128","author":"Norquist","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2017.06.002_bb0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.7326\/0003-4819-143-5-200509060-00011","article-title":"Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement","volume":"143","author":"U.S. Preventive Services Task Force","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0015","author":"SGO Position Statement"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.06.002_bb0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/gim.2014.147","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0030","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/AOG.0b013e3181da08d7","article-title":"Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities","volume":"115","author":"Meyer","year":"2010","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2008.10.007","article-title":"Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based study","volume":"112","author":"Metcalfe","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0040","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/GIM.0b013e3182091ba4","article-title":"Underutilization of BRCA1\/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk","volume":"13","author":"Levy","year":"2011","journal-title":"Genet. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2017.06.002_bb0045","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1002\/cncr.29645","article-title":"A high frequency of BRCA mutations in young black women with breast cancer residing in Florida","volume":"121","author":"Pal","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0050","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0055","author":"Food and Drug Administration Approved Drugs"},{"issue":"1","key":"10.1016\/j.ygyno.2017.06.002_bb0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2017.06.002_bb0070","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0075","series-title":"Late Breaking Abstract 3, SGO 47th Annual Meeting on Women's Cancer, San Diego, CA","article-title":"Preliminary results of a phase II study: PD-1 blockade in mismatch repair\u2013deficient, recurrent or persistent endometrial cancer","author":"Fader","year":"2016"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0080","author":"CDC"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0085","author":"The Precision Medicine Initiative"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0090","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0095","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0100","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0105","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/hmg\/10.7.705","article-title":"BRCA1 and BRCA2 and the genetics of breast and ovarian cancer","volume":"10","author":"Welcsh","year":"2001","journal-title":"Hum. Mol. Genet."},{"issue":"22","key":"10.1016\/j.ygyno.2017.06.002_bb0110","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0115","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0120","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1158\/1078-0432.CCR-14-2497","article-title":"Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer","volume":"21","author":"Candido-dos-Reis","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jnci\/djs494","article-title":"Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2","volume":"105","author":"McLaughlin","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0130","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/bjc.2013.70","article-title":"BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study","volume":"108","author":"Lesnock","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0135","series-title":"Abstract 1, SGO 47th Annual Meeting on Women's Cancer, San Diego, CA","article-title":"Mutations in homologous recombination genes and response to treatment in GOG 218: an NRG Oncology study","author":"Norquist","year":"2016"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ygyno.2011.12.415","article-title":"Hereditary ovarian cancer: beyond the usual suspects","volume":"124","author":"Pennington","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0145","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0150","first-page":"1","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"30","author":"Norquist","year":"2015","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.06.002_bb0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2016.03.007","article-title":"The genetic prediction of risk for gynecologic cancers","volume":"141","author":"Randall","year":"2016","journal-title":"Gynecol Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.06.002_bb0160","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.AOG.0000154885.44002.ae","article-title":"Gynecologic cancer as a \u201csentinel cancer\u201d for.women with hereditary nonpolyposis colorectal cancer syndrome","volume":"105","author":"Lu","year":"2005","journal-title":"Obstet. Gynecol."},{"issue":"36","key":"10.1016\/j.ygyno.2017.06.002_bb0165","doi-asserted-by":"crossref","first-page":"9344","DOI":"10.1200\/JCO.2005.03.5915","article-title":"Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome?","volume":"23","author":"Soliman","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.06.002_bb0170","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ygyno.2009.11.021","article-title":"Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening","volume":"116","author":"Walsh","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0175","article-title":"Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG oncology\/gynecologic oncology group study","volume":"20","author":"McMeekin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0180","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1097\/01.AOG.0000466373.71146.51","article-title":"Hereditary cancer syndromes and risk assessment","volume":"125","author":"Committee opinion no. 634","year":"2015","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0185","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djh034","article-title":"Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability","volume":"96","author":"Umar","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0190","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/01.AOG.0000456325.50739.72","article-title":"ACOG practice bulletin no. 147: lynch syndrome","volume":"124","author":"Committee on Practice Bulletins-Gynecology Society of Gynecologic Oncology","year":"2014","journal-title":"Obstet. Gynecol."},{"issue":"8","key":"10.1016\/j.ygyno.2017.06.002_bb0195","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1200\/JCO.2013.51.4661","article-title":"Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology quality oncology practice initiative","volume":"32","author":"Wood","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0200","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10897-013-9588-0","article-title":"Identification of genetic counseling service delivery models in practice: a report from the NSGC Service Delivery Model Task Force","volume":"22","author":"Cohen","year":"2013","journal-title":"J. Genet. Couns."},{"issue":"31","key":"10.1016\/j.ygyno.2017.06.002_bb0205","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","article-title":"American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility","volume":"33","author":"Robson","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2017.06.002_bb0210","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/gim.2015.98","article-title":"The current state of cancer genetic counseling access and availability","volume":"18","author":"Knapke","year":"2015","journal-title":"Genet Med."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0215","author":"U.S. Department of Health & Human Services"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0220","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2013.51.3226","article-title":"Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer","volume":"32","author":"Scwartz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0225","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10689-010-9369-y","article-title":"Real world experience with cancer genetic counseling via telephone","volume":"9","author":"Sutphen","year":"2010","journal-title":"Familial Cancer"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0230","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2013.51.3226","article-title":"Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer","volume":"32","author":"Schwartz","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.06.002_bb0235","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s10897-015-9897-6","article-title":"Patient perceptions of telephone vs. in-person BRCA1\/BRCA2 genetic counseling","volume":"25","author":"Peshkin","year":"2015","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0240","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10897-015-9836-6","article-title":"Randomized trial of telegenetics vs. in-person cancer genetic counseling: cost, patient satisfaction and attendance","volume":"24","author":"Buchanan","year":"2015","journal-title":"J. Genet. Couns."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0245","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/GIM.0b013e3182217a19","article-title":"Are videoconferenced consultations as effective as face-to-face consultations for hereditary breast and ovarian cancer genetic counseling?","volume":"13","author":"Zilliacus","year":"2011","journal-title":"Genet Med."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0250","author":"Supreme Court of the United States"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0255","series-title":"An Introduction to Genetic Analysis","author":"Griffiths","year":"2000"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0260","doi-asserted-by":"crossref","unstructured":"De, S. Somatic mosaicism in healthy human tissues. Trends Genet., Volume 27(6):217\u2013223.","DOI":"10.1016\/j.tig.2011.03.002"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0265","author":"NCCN"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0270","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/gim.2014.40","article-title":"Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients","volume":"16","author":"LaDuca","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0275","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.29010","article-title":"Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel","volume":"121","author":"Tung","year":"2015","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2017.06.002_bb0280","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/gim.2014.40","article-title":"Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients","volume":"16","author":"LaDuca","year":"2014","journal-title":"Genet Med."},{"issue":"1","key":"10.1016\/j.ygyno.2017.06.002_bb0285","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.29010","article-title":"Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel","volume":"121","author":"Tung","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0290","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2041-2223-2-23","article-title":"Next-generation sequencing technologies and applications for human genetic history and forensics","volume":"2","author":"Berglund","year":"2011","journal-title":"Investig. Genet."},{"issue":"2","key":"10.1016\/j.ygyno.2017.06.002_bb0295","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ygyno.2015.02.017","article-title":"Two decades beyond BRCA1\/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy","volume":"137","author":"Walsh","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0300","author":"Food and Drug Administration"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0305","author":"Food and Drug Administration"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0310","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.2003.10.100","article-title":"Long-term psychological impact of carrying a BRCA1\/2 mutation and prophylactic surgery: a 5-year follow-up study","volume":"21","author":"van Oostrom","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0315","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.20.2.514","article-title":"Impact of BRCA1\/BRCA2 mutation testing on psychologic distress in a clinic-based sample","volume":"20","author":"Schwartz","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0320","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10689-008-9182-z","article-title":"Psychological and cancer-specific distress at 18months post-testing in women with demonstrated BRCA1 mutations for hereditary breast\/ovarian cancer","volume":"7","author":"Reichelt","year":"2008","journal-title":"Familial Cancer"},{"key":"10.1016\/j.ygyno.2017.06.002_bb0325","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/GIM.0b013e31815f524f","article-title":"A systematic review of perceived risks, psychological and behavioral impacts of genetic testing","volume":"10","author":"Heshka","year":"2008","journal-title":"Genet Med."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0330","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1037\/a0014778","article-title":"Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review","volume":"28","author":"Hamilton","year":"2009","journal-title":"Health Psychol."},{"key":"10.1016\/j.ygyno.2017.06.002_bb0335","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jnci\/dju379","article-title":"Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial","volume":"107","author":"Manchanda","year":"2015","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T13:31:08Z","timestamp":1584019868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817308971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0090825817308971"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.06.002","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}